Clinical Coagulation, Malmö
16 – 30 of 629
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
2023) In Haemophilia(
- Contribution to journal › Article
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
(
- Contribution to journal › Article
-
Mark
Association of Circulating Long Noncoding 7S RNA with Deep Vein Thrombosis
(
- Contribution to journal › Article
-
Mark
Entrustable professional activities (EPAs) for undergraduate medical education – development and exploration of social validity
(
- Contribution to journal › Article
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Lung function, respiratory symptoms and incident venous thromboembolism during a 44-year follow-up
(
- Contribution to journal › Article
-
Mark
Novel methodology for the evaluation of symptoms reported by patients with newly diagnosed atrial fibrillation : Application of natural language processing to electronic medical records data
(
- Contribution to journal › Article
-
Mark
Koagulationsfaktor XIII – inte bara ett kongenitalt blödningsproblem
(
- Contribution to journal › Scientific review
-
Mark
Effect of dronedarone vs. placebo on atrial fibrillation progression : a post hoc analysis from ATHENA trial
2023) In Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 25(3). p.845-854(
- Contribution to journal › Article
-
Mark
Considerations for shared decision management in previously untreated patients with hemophilia A or B
(
- Contribution to journal › Scientific review
-
Mark
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice
(
- Contribution to journal › Article
-
Mark
Validation of immunofluorescence analysis of blood smears in patients with inherited platelet disorders
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in development
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B : post hoc analysis of phase III trials using patient-reported outcomes
(
- Contribution to journal › Article